A 2026 laboratory study found no detectable acute-pain increase in frequent cannabis users after at least 12 hours of biochemically verified abstinence. Frequent users had higher THC exposure and higher plasma cannabinoid markers, but pain threshold, pain tolerance, and pain ratings did not differ from occasional users.1 Research Highlights 75 healthy adults were tested: Pabon …
A 2025 survey of 686 Dutch university students linked violent pornography use to self-reported sexual aggression risk, especially when pornography was perceived as realistic or when peer rape myth acceptance was higher. Research Highlights 686 students were surveyed: the Dutch online sample was 63.4% female and focused on pornography use, perceived realism, peer rape myth …
A 2026 randomized exploratory pilot found that a single 24-minute yoga session did not significantly lower salivary cortisol or salivary alpha-amylase compared with quiet sitting in 19 stressed adults.1 The acute yoga signal was physiological but not the simple stress-biomarker drop that wellness claims often imply. Research Highlights Biomarker claim failed: Yoga did not significantly …
In a 2,411-person multinational twin-consortium study, depressive symptoms increased significantly as death approached. The strongest design check compared twins directly: twins who died had larger terminal symptom increases than co-twins who survived at least 4 more years. Research Highlights Terminal mood change was visible: Petkus et al. found accelerated depressive-symptom increases roughly 4.3 years before …
A 2026 structural MRI study found that cerebellar gray-matter patterns helped distinguish first-episode bipolar depression from unipolar depression: a model using significant cerebellar lobules reached 76.3% accuracy and AUC 0.779.1 The result is best read as proof-of-concept neuroimaging evidence, not as a scan-based bipolar diagnostic test. Research Highlights Classifier performance was moderate: cerebellar lobules with …
A 2026 medRxiv preprint using parent-cocreated sensory-related outcome measures found that 83% of children and teens improved on at least 1 PROMIS domain during 6 months of bumetanide treatment.1 The result is interesting, but the unmasked single-case design means the strongest claim is about sensitive outcome tracking, not definitive bumetanide efficacy. Research Highlights Most participants …
A 2026 medRxiv preprint built a reusable NeuroMark SPECT template from 2 large independent component analysis rounds, then applied it to 137 schizophrenia patients and 76 controls; after false-discovery-rate correction, 23 of 68 perfusion components differed between groups.1 Those data support infrastructure for comparing SPECT perfusion networks across datasets, with standalone schizophrenia diagnosis left outside …